Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00333554 · ClinicalTrials.gov registry record · NA
Nutritional Intervention to Prevent Diabetes
A NA study of Type 1 Diabetes Mellitus, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- NA
- Development phase
- 99
- Enrollment target
- 9
- Study locations
NCT00333554 is a NA study of Type 1 Diabetes Mellitus that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 99 participants, below the 139-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (29% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT00333554, a NA study of Type 1 Diabetes Mellitus, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- NA
- Development phase
- 99 participants
- Enrollment target
- 9
- Study locations
Study Summary
Type 1 Diabetes (T1D) is an autoimmune disease. This means that the immune system (the part of the body which helps fight infections) mistakenly attacks and destroys the cells that produce insulin (islet cells found in the pancreas). As these cells are destroyed, the body's ability to produce insulin decreases. The autoimmune process is thought to be initiated by a gene-environment interaction. The genetics involved in the development of T1D are fairly well understood. There is a higher risk of developing T1D with the presence of the human leukocyte antigen (HLA) DR3 or DR4. It is also known that not everyone with these genes actually develops T1D. Therefore, one or more environmental factors are thought to contribute to the process of developing T1D. The consumption of the anti-inflammatory fatty acids, the omega-3 fatty acids, has decreased significantly in the past 100 years. At the same time a rise in the incidence of T1D, especially in young children has occurred. Because of the warnings to eliminate fish during pregnancy, pregnant women are consuming even less omega-3 fatty acids during fetal development. Observations have been made that children who have received omega-3 fatty acid supplementation have a lower risk of T1D. Omega-3 fatty acids could have a protective effect that may occur during pregnancy, infancy, or both. The mechanism of this protection may be due to the DHA mediated suppression of the inflammatory response. Patients at higher risk for T1D have an increased pro-inflammatory environment. We hypothesize that DHA supplementation during pregnancy and early childhood will block the initial pro-inflammatory events and prevent development of islet cell autoimmunity in children at higher risk for T1D. This study is a feasibility study to determine if a full-scale DHA supplementation study will be implemented. If a full study is implemented, the primary outcome will be to determine if nutritional supplementation with omega-3 fatty acids during
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT DHA Treatment
- DIETARY_SUPPLEMENT Placebo for DHA
Study Locations (9)
California
- Childrens Hospital of Los Angeles - Los Angeles
- Children's Hospital of Orange County - Orange
- University of California, San Francisco - San Francisco
Indiana
- Indiana University-Riley Hospital for Children - Indianapolis
Iowa
- University of Iowa Health Care - Iowa City
Massachusetts
- Joslin Diabetes Center - Boston
Minnesota
- University of Minnesota - Minneapolis
Missouri
- The Children's Mercy Hospital - Kansas City
Utah
- Utah Diabetes Center - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2006-06 |
| Est. Completion | 2013-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00333554
The ClinicalTrials.gov registry entry for NCT00333554 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (29% lower). The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which DHA Treatment is the first listed.
NCT00333554 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, Indiana, Iowa.
Frequently Asked Questions
What is clinical trial NCT00333554 about?
NCT00333554 is a clinical study titled "Nutritional Intervention to Prevent Diabetes". Type 1 Diabetes (T1D) is an autoimmune disease. This means that the immune system (the part of the body which helps fight infections) mistakenly attacks and destroys the cells that produce insulin (islet cells found in the pancreas). As these cells are destroyed, the body's ability to produce insuli...
What is the current status of trial NCT00333554?
This trial is currently completed. It is a NA study. The enrollment target is 99 participants. The study started on 2006-06. Estimated completion is 2013-04.
What conditions does trial NCT00333554 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT00333554?
The interventions under investigation include: DHA Treatment (DIETARY_SUPPLEMENT), Placebo for DHA (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00333554?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00333554 being conducted?
This trial has 9 study locations across California, Indiana, Iowa, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM
RECRUITING · NA
-
Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)
RECRUITING · NA
-
A Hybrid Effectiveness-implementation Trial to Reduce Diabetes Distress in Teenagers
RECRUITING · NA
-
PACTAID App in Adults With Type 1 Diabetes to Help Manage Exercise
RECRUITING · NA
-
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
RECRUITING · NA
-
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.